Mersana Therapeutics to Present at Upcoming Investor Conferences
Mersana Therapeutics (NASDAQ: MRSN), a clinical-stage biopharmaceutical company specializing in antibody-drug conjugates (ADCs) for cancer treatment, has announced its participation in two upcoming investor conferences. The company will participate in a fireside chat at the TD Cowen 6th Annual Oncology Innovation Summit on May 27, 2025, at 2:00 p.m. ET, and deliver a presentation at the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025, at 2:00 p.m. ET. Both events will be webcast live and available on Mersana's website, with replays accessible for approximately 90 days.
Mersana Therapeutics (NASDAQ: MRSN), un'azienda biofarmaceutica in fase clinica specializzata in coniugati anticorpo-farmaco (ADC) per il trattamento del cancro, ha annunciato la sua partecipazione a due prossimi eventi per investitori. L'azienda prenderà parte a una chiacchierata informale al TD Cowen 6th Annual Oncology Innovation Summit il 27 maggio 2025 alle 14:00 ET, e terrà una presentazione al Goldman Sachs 46th Annual Global Healthcare Conference il 9 giugno 2025 alle 14:00 ET. Entrambi gli eventi saranno trasmessi in diretta streaming e disponibili sul sito web di Mersana, con le registrazioni accessibili per circa 90 giorni.
Mersana Therapeutics (NASDAQ: MRSN), una empresa biofarmacéutica en etapa clínica especializada en conjugados anticuerpo-fármaco (ADC) para el tratamiento del cáncer, ha anunciado su participación en dos próximas conferencias para inversores. La compañía participará en una charla informal en el TD Cowen 6th Annual Oncology Innovation Summit el 27 de mayo de 2025 a las 2:00 p.m. ET, y realizará una presentación en la Goldman Sachs 46th Annual Global Healthcare Conference el 9 de junio de 2025 a las 2:00 p.m. ET. Ambos eventos se transmitirán en vivo por internet y estarán disponibles en el sitio web de Mersana, con repeticiones accesibles durante aproximadamente 90 días.
Mersana Therapeutics (NASDAQ: MRSN)는 암 치료를 위한 항체-약물 접합체(ADC)를 전문으로 하는 임상 단계의 바이오제약 회사로, 다가오는 두 개의 투자자 컨퍼런스에 참여할 예정임을 발표했습니다. 회사는 2025년 5월 27일 오후 2시(동부시간)에 열리는 TD Cowen 6th Annual Oncology Innovation Summit에서 파이어사이드 채팅에 참여하며, 2025년 6월 9일 오후 2시(동부시간)에 열리는 Goldman Sachs 46th Annual Global Healthcare Conference에서 발표를 진행할 예정입니다. 두 행사 모두 생중계되며 Mersana 웹사이트에서 시청할 수 있고, 약 90일 동안 다시보기 서비스도 제공됩니다.
Mersana Therapeutics (NASDAQ : MRSN), une société biopharmaceutique en phase clinique spécialisée dans les conjugués anticorps-médicament (ADC) pour le traitement du cancer, a annoncé sa participation à deux prochaines conférences pour investisseurs. La société participera à une discussion informelle lors du TD Cowen 6th Annual Oncology Innovation Summit le 27 mai 2025 à 14h00 ET, et présentera lors du Goldman Sachs 46th Annual Global Healthcare Conference le 9 juin 2025 à 14h00 ET. Les deux événements seront diffusés en direct sur le site web de Mersana, avec des rediffusions disponibles pendant environ 90 jours.
Mersana Therapeutics (NASDAQ: MRSN), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Antikörper-Wirkstoff-Konjugate (ADCs) zur Krebsbehandlung spezialisiert hat, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt. Das Unternehmen wird am TD Cowen 6th Annual Oncology Innovation Summit am 27. Mai 2025 um 14:00 Uhr ET an einem Fireside-Chat teilnehmen und am Goldman Sachs 46th Annual Global Healthcare Conference am 9. Juni 2025 um 14:00 Uhr ET eine Präsentation halten. Beide Veranstaltungen werden live im Webcast übertragen und auf der Website von Mersana verfügbar sein, mit Wiedergaben, die etwa 90 Tage lang zugänglich sind.
- None.
- None.
CAMBRIDGE, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will participate in the following upcoming investor events:
- TD Cowen 6th Annual Oncology Innovation Summit
Format: Fireside chat
Date/Time: Tuesday, May 27, 2025, at 2:00 p.m. Eastern Time - Goldman Sachs 46th Annual Global Healthcare Conference
Format: Presentation
Date/Time: Monday, June 9, 2025, at 2:00 p.m. Eastern Time
Live webcasts of these events will be available on the Investors & Media section of Mersana’s website at www.mersana.com. Archived replays will be available for approximately 90 days following the events.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that have generated a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Mersana routinely posts information that may be useful to investors on the “Investors & Media” section of its website at www.mersana.com.
Contact:
Jason Fredette
617-498-0020
jason.fredette@mersana.com
FAQ
What investor conferences will Mersana Therapeutics (MRSN) attend in May-June 2025?
How can investors access Mersana Therapeutics' (MRSN) conference presentations?
What is Mersana Therapeutics' (MRSN) main business focus?
What type of presentation will MRSN give at each conference?
